Bruce Cozadd

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze. The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. Financial Highlights GAAP net income for Q2 2023 stood at $104.4 million, reflecting an increase from $34.7 million in the same period...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022. Net income was $69.4 million, or $1.04 per diluted share, compared to $1.6 million, or $0.03 per diluted...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights GAAP net loss for 2022 was $(224.1) million, or $(3.58) per diluted share, compared to $(329.7) million, or $(5.52) per diluted share, for 2021...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics, Inc. (NASDAQ: AXSM). Deal Details Under the terms of the agreement, Jazz received an upfront payment of $53 million, and will receive a high single-digit royalty on...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022. Financial Highlights Q1 2022 GAAP net income was $1.6 million, or $0.03 per diluted share, a drop of 98.68% compared to $121.8 million, or $2.09 per diluted share, in the same period in 2021. Total...

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC) against GW Pharmaceuticals on Feb. 25th. The lawsuit was initially filed in 2020, and since then, Britain’s GW Pharma was...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...

Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the comparative period of 2020. Financial...

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders. The Jazz-GW...

Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) surged higher by more than 70 percent early Tuesday morning after the company has agreed to be acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for approximately $1.5 billion, or $30.25 per share. Celator's stock closed for trading at...